Business Context and Reporting Period
This Form 8-K Current Report was filed by Neuralstem, Inc. on April 12, 2012, regarding events occurring on April 9, 2012. The filing addresses Item 5.02 concerning the departure of a senior officer and the appointment of an interim replacement.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes rather than financial performance.
Material Changes
- Departure of CFO: John Conron resigned as Chief Financial Officer and principal accounting officer effective immediately on April 9, 2012, due to retirement. The resignation was not the result of any disagreement with the Company or its management.
- Interim Appointment: I. Richard Garr, the Company's President, Chief Executive Officer, and General Counsel, was appointed as Interim Chief Financial Officer and acting principal financial officer effective April 9, 2012.
Management Commentary and Risks
Management confirmed that the transition was amicable. Mr. Garr, who has served as CEO and a director since 1996, brings extensive experience in the neural stem cell field. The filing notes no family relationships between Mr. Garr and other officers or directors. No specific financial risks, contingencies, or unusual items were disclosed in this document.
Investor Verification Checklist
- Verify the timeline for the search for a permanent Chief Financial Officer.
- Review subsequent filings to confirm the appointment of a permanent CFO.
- Check for any related party transactions involving the interim CFO.
- Confirm that the resignation of the previous CFO did not impact the accuracy of prior financial statements.